P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB
HemaSphere | June 30, 2022 | Volume: 6 | Issue: No issue available | Pages: 852-853
10.1097/01.hs9.0000846716.90763.d0